<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460707</url>
  </required_header>
  <id_info>
    <org_study_id>NKV109990</org_study_id>
    <nct_id>NCT00460707</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to
      test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy
      human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2007</start_date>
  <completion_date type="Actual">August 27, 2007</completion_date>
  <primary_completion_date type="Actual">August 27, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of casopitant and ketoconazole will be checked on Day 4 to 9 in Cohort 1.</measure>
    <time_frame>Day 4 to 9 in Cohort 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of casopitant will be checked on Day 2 to 4 of Period 1 and</measure>
    <time_frame>Day 2 to 4 of Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>casopitant and ketoconazole will be checked on Day 4 to 9 of Period 2.</measure>
    <time_frame>Day 4 to 9 of Period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety is evaluated in Cohort 1 by: - Clinical Lab Tests &amp; Physical Exam at Screen, Day -1 &amp; Followup (FU)</measure>
    <time_frame>at Screen, Day -1 &amp; Followup (FU)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Vitals Signs monitored at Screen, Day -1, 4-7 and FU</measure>
    <time_frame>at Screen, Day -1, 4-7 and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- 12 lead ECGs at Screen &amp; FU</measure>
    <time_frame>at Screen &amp; FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Adverse Events Monitoring starting at Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Nausea and Vomiting, Chemotherapy-Induced</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casopitant 150 mg</intervention_name>
    <description>Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.</description>
    <arm_group_label>Cohort 2, Group B</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).</description>
    <arm_group_label>Cohort 2, Group B</arm_group_label>
    <arm_group_label>Cohort 2, Group A</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Casopitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casopitant 150 mg matching placebo</intervention_name>
    <description>Casopitant 150 mg matching placebo will be available as white, film-coated tablets.</description>
    <arm_group_label>Cohort 2, Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casopitant 50 mg</intervention_name>
    <description>Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.</description>
    <arm_group_label>Cohort 2, Group B</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casopitant 50 mg matching placebo</intervention_name>
    <description>Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.</description>
    <arm_group_label>Cohort 2, Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A female subject who is non-childbearing potential or using acceptable contraceptive
             methods.

          -  Adequate organ system functions.

          -  Able to swallow and retain oral medication.

          -  Subject is able to understand and comply with protocol requirements and instruction
             and is likely to complete the study.

        Exclusion Criteria:

          -  Current clinically relevant abnormality, medical condition, or circumstance that makes
             the subject unsuitable for the study per the study doctor.

          -  History of drug or other allergy which, in the opinion of the study doctor,
             contraindicates participation.

          -  Use of an investigational drug within 28 days or 5 half-lives.

          -  Use of prescription or non-prescription drugs, supplements or vitamins (excluding
             multivitamins) within 14 days, or 5 half-lives prior to first dose of study
             medication.

          -  Blood donation in excess of 500mL within 56 days prior to dosing or intends to donate
             within 30 days of the post-treatment follow-up visit.

          -  Iron deficiency.

          -  Positive stool for occult blood.

          -  Female subject who is pregnant or lactating.

          -  Male subject who has a history of hypogonadism.

          -  Positive urine drug screen.

          -  Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen.

          -  Use of tobacco-containing products within the past 12 months prior to screening.

          -  History of drug or alcohol abuse or dependence within 6 months of screening.

          -  History or presence of uncontrolled emesis.

          -  Presence of active infection.

          -  History of cholecystectomy or biliary tract disease.

          -  Active peptic ulcer disease (PUD) or a history of PUD of unknown etiology.

          -  Any degree of heart failure.

          -  Consumption of any food or drink containing grapefruit or grapefruit juice, apple
             juice, Seville oranges, kumquats, pommelos or vegetables from the mustard green family
             within 7 days prior to the first dose unless prior approval is received.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/NKV109990?search=study&amp;search_terms=109990#rs</url>
    <description>Results for study 109990 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Johnson BM, Adams LM, Zhang K, Gainer SD, Kirby LC, Blum RA, Apseloff G, Morrison RA, Schutz RA, Lebowitz PF. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9. doi: 10.1177/0091270009353761. Epub 2010 Feb 2.</citation>
    <PMID>20124517</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW679769</keyword>
  <keyword>healthy adult subjects</keyword>
  <keyword>casopitant</keyword>
  <keyword>ketoconazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Casopitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>NKV109990</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV109990</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV109990</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV109990</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV109990</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV109990</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV109990</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

